Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection
Stopped Study terminated on the recommendation of an independent Data Monitoring Committee (DMC) subsequent to an interim efficacy analysis for futility.\]
Conditions
Interventions
- DRUG: Telbivudine
- DRUG: Placebo
Sponsor
Novartis Pharmaceuticals